

eTable 1. Participant Baseline Demographics and Clinical Characteristics by Headache Severity^a

	Participants who Only Treated Attacks with Mild Pain		Participants who Only Treated Attacks with Moderate or Severe Pain		Participants who Treated Attacks with Both Mild and Moderate or Severe Pain	
	Ubrogepant 50 mg	Ubrogepant 100 mg	Ubrogepant 50 mg	Ubrogepant 100 mg	Ubrogepant 50 mg	Ubrogepant 100 mg
Age (years), n	9	4	173	178	209	217
Mean (SD)	42.4 (9.6)	40.0 (16.2)	42.0 (12.0)	40.8 (10.8)	42.5 (12.5)	42.1 (11.6)
Min, Max	26, 57	25, 63	18, 72	18, 70	18, 71	18, 73
Sex, n (%)						
Female	8 (88.9)	4 (100)	154 (89.0)	161 (90.5)	198 (94.7)	193 (88.9)
Male	1 (11.1)	0 (0)	19 (11.0)	17 (9.6)	11 (5.3)	24 (11.1)
Race, n (%)						
White	8 (88.9)	3 (75.0)	152 (87.9)	149 (83.7)	180 (86.1)	180 (83.0)
Black/African American	1 (11.1)	0 (0)	19 (11.0)	23 (12.9)	25 (12.0)	30 (13.8)
Other^b	0 (0)	1 (25.0)	2 (1.2)	6 (3.4)	4 (1.9)	7 (3.2)
BMI (kg/m²), n	9	4	173	178	208	217
Mean (SD)	25.8 (5.2)	30.8 (10.7)	30.6 (7.7)	31.0 (8.4)	28.5 (6.8)	29.4 (7.5)
Min, Max	20.0, 33.5	20.8, 43.5	17.4, 54.3	16.7, 56.4	17.1, 51.1	17.8, 53.9
Concomitant Preventive Migraine Medication, n (%)	2 (22.2)	1 (25.0)	40 (23.1)	45 (25.3)	56 (26.8)	53 (24.4)

^a Participants may be counted in both subgroups if they treated an attack of mild and moderate or severe pain during the trial.

^b Other includes Asian, American Indian or Alaska native, native Hawaiian or other Pacific Islander, and those who reported multiple races.